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The Pictorial Representation of Illness and Self Measure
(PRISM) instrument reveals a high burden of suffering in
patients with chronic urticaria
Abstract
PRISM revealed a high burden of suffering in chronic urticaria and provided helpful additional
information for the management of these patients. In our cohort, cognitive flexibility was a positive
predictive marker for the course of chronic urticaria.
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■ Abstract
Background: Chronic urticaria severely affects quality of life. To date, no gold standard has been established to measure the burden of 
suffering, which often correlates poorly with the skin symptoms observed in patients with chronic urticaria.
Objective: To investigate the effect of psychological factors on the course of urticaria.
Methods: Health-related quality of life was assessed in 95 patients with chronic urticaria using the following instruments: Pictorial 
Representation of Illness and Self Measure (PRISM), Dermatology Life Quality Index (DLQI), and Skindex-29. Correlations were calculated. 
Cognitive fl exibility and its correlation with the course of urticaria were assessed. Two case reports are presented to further elucidate 
features of PRISM.
Results: PRISM revealed a high burden of suffering that was consistent with considerably impaired quality of life as measured by DLQI and 
Skindex-29 in the same patients. However, no signifi cant correlation was observed between PRISM and the 2 quality of life questionnaires. 
From the baseline visit to the follow-up visit, quality of life scores improved signifi cantly (DLQI, P=.001; Skindex-29, P=.001), whereas 
the PRISM score remained unchanged (P=.085). Disease course was favorable more often in cognitively fl exible patients (n=54) (91%) 
than cognitively infl exible patients (P=.007).
Conclusions: PRISM revealed a high burden of suffering in chronic urticaria and provided helpful additional information for the management 
of these patients. In our cohort, cognitive fl exibility was a positive predictive marker for the course of chronic urticaria. 
Key words: DLQI. PRISM. Quality of life. Skindex-29. Urticaria.
■ Resumen
Antecedentes: La urticaria crónica afecta gravemente a la calidad de vida. Hasta la fecha, no se ha establecido un método de referencia para 
medir la carga de sufrimiento que suele estar poco relacionada con los síntomas cutáneos observados en pacientes con urticaria crónica.
Objetivo: Estudiar el efecto de factores psicológicos sobre la evolución de la urticaria.
Métodos: Se evaluó repetidas veces la calidad de vida relacionada con la salud en 95 pacientes con urticaria crónica mediante los 
instrumentos siguientes: Pictorial Representation of Illness and Self Measure (PRISM), Índice de calidad de vida en dermatología (DLQI) y 
el cuestionario Skindex-29. Se calcularon las correlaciones. Se evaluaron la fl exibilidad cognitiva y su correlación con la evolución de la 
urticaria. Se presentan dos casos clínicos para demostrar mejor las características del PRISM.
Resultados: El PRISM reveló una carga elevada de sufrimiento en consonancia con una calidad de vida considerablemente afectada 
determinada mediante los cuestionarios DLQI y Skindex-29 en los mismos pacientes. No obstante, no se observó una correlación signifi cativa 
entre el PRISM y los 2 cuestionarios de calidad de vida. Desde la visita inicial hasta la de seguimiento, las puntuaciones de calidad de 
vida mejoraron signifi cativamente (DLQI, p=0,001; Skindex-29, p=0,001), mientras que la puntuación del PRISM se mantuvo igual (p = 
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Introduction
Chronic urticaria is a common skin disease that is 
characterized by spontaneous itchy wheals. It affects 0.5%-1% 
of the general population, with an average age of 41 years [1]. 
If physical urticaria and urticarial vasculitis are not taken into 
consideration, autoimmune chronic urticaria accounts for 45% 
of cases and idiopathic chronic urticaria for 55% [2]. Defi ned 
as urticaria symptoms every day or on most days for more 
than 6 weeks, chronic urticaria has a considerable impact on 
patients’ lives [3,4]. Several validated dermatology-specifi c 
health-related quality of life questionnaires are available. The 
best known are the Dermatology Life Quality Index (DLQI), 
developed by Finlay et al [5], and Skindex-29, developed by 
Chren et al [6]. However, few instruments assess burden of 
suffering in patients with chronic urticaria. A novel tool to 
assess suffering–the Pictorial Representation of Illness and 
Self-Measure (PRISM) [7]–has been developed and validated 
in dermatological inpatients [8]. 
Chronically ill patients may have a reduced ability to 
perceive and express differences in the symptoms and impact of 
their disease [9], and this reduced ability can be understood as a 
neurophysiological correlate of the so called chronicity associated 
with poor outcomes [10]. PRISM has been shown to assess the 
ability to perceive and express relevant differences in the impact 
of a disease. This ability is known as cognitive fl exibility [11]. 
The aim of this study was to validate PRISM, a nonverbal 
visualization technique to assess the burden of suffering in 
patients with chronic urticaria, and to compare it with the 
self-administered quality of life questionnaires DLQI and 
Skindex-29. Furthermore, we investigated whether cognitive 
fl exibility, as assessed by PRISM during the fi rst visit, had an 
impact on the course of chronic urticaria. Our hypothesis was 
that cognitively fl exible patients might have a better outcome 
than cognitively infl exible patients.
Material and Methods
Patient Characteristics
A specialty clinic for urticaria patients was established at 
the Department of Dermatology of the University Hospital of 
Zurich. From January 2007 to January 2008 all eligible patients 
suffering from chronic urticaria were prospectively recruited 
and monitored over a period of 4 months. Chronic urticaria was 
defi ned according to the guidelines of the European Academy of 
0,085). Los pacientes con un perfi l cognitivo fl exible (n=54) presentaron con mayor frecuencia una evolución favorable de la enfermedad 
(91%) que los pacientes con un perfi l cognitivo rígido (p=0,007).
Conclusiones: El PRISM reveló una alta carga de sufrimiento en la urticaria crónica y proporcionó información adicional útil para el 
tratamiento de estos pacientes. En la cohorte estudiada, la fl exibilidad cognitiva fue un marcador predictivo positivo de la evolución de 
la urticaria crónica. 
Palabras clave: DLQI. PRISM. Calidad de vida. Skindex-29. Urticaria.
Allergy and Clinical Immunology, the Global Allergy and Asthma 
European Network, and the European Dermatology Forum [4]. 
Patients with acute urticaria or other skin diseases and patients 
younger than 12 years were excluded. Five patients (5.3%) had 
physical urticaria (2 with cold urticaria, 2 with pressure urticaria, 
and 1 with friction urticaria). The local ethics committee approved 
the study protocol (reference number EK 705) and all patients 
gave their written informed consent to participate. Patients were 
questioned about their clinical symptoms. Impairment of quality 
of life was assessed using the DLQI and Skindex-29; burden of 
suffering was assessed using PRISM at the fi rst visit and at a 
follow-up visit after 4 months.
The PRISM Task
PRISM has been validated to measure burden of suffering 
in a variety of chronic diseases [8,12,13] and was applied in this 
study as described elsewhere [7,14]. Briefl y, the patient is shown a 
white A4-sized metal board with a fi xed yellow disk (representing 
the patient’s self) at the bottom right-hand corner and asked to 
imagine that the board represents his/her life as it is at the time. 
The patient is then handed a red disk, asked to imagine that this 
represents his/her illness, and then asked 2 questions–1) Where in 
your life (board) would you place the urticaria disk at the moment? 
and 2) Where would you place the urticaria disk in regard to 
the last 2 weeks?–to refl ect the importance of the illness in his/
her life. The main quantitative measure derived from PRISM is 
the Self–Illness Separation (SIS), namely, the distance in 
millimeters –between the centers of the illness and the self disks. 
The possible range for the SIS is 0-273 mm, with smaller values 
representing greater suffering (Figure 1). 
Self-Illness Separation (SIS)
Figure 1. The PRISM task (see Material and Methods). DLQI indicates 
Dermatology Life Quality Index; PRISM, Pictorial Representation of Illness 
and Self Measure.
PRISM: Suffering in Chronic Urticaria
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PRISM has been shown to sensitively assess treatment 
effects in chronic disease [14] and to have the capacity to assess 
differences in a patient’s cognitive fl exibility [11], defi ned in 
this study as a variation in SIS between questions (i) and (ii) 
greater than 10%. Patients were rated fl exible, worse if SIS at 
the fi rst visit was more than 10% smaller for question 1 than 
for question 2, infl exible if PRISM values differed no more than 
10% between questions 1 and 2, or fl exible, better if PRISM 
yielded more than 10% better values for question 1. 
Patients assessed the clinical outcome of urticaria using 
written charts in which they recorded presence or absence of 
urticaria daily during the study. Improvement was defi ned as a 
reduction of at least 25% in the number of days with urticaria 
symptoms during the month before the 4-month follow-up 
visit. Patients with an improvement of less than 25% or 
deterioration of urticaria were classed as unimproved. 
Dermatology Life Quality Index
Originally developed for patients with psoriasis, the DLQI 
is a simple and validated 10-item questionnaire designed to 
measure and compare disability arising from several skin 
conditions [5]. It is used as an assessment tool in daily clinical 
practice [15,16]. Patients used the DLQI to indicate, on a scale 
from 0 to 3 for each of the 10 items, how their skin condition 
infl uenced quality of life at the time of the assessment and the 
week before. The total score ranges from 0 to 30: the higher 
the score, the greater the disability. 
Skindex-29
Quality of life was also assessed using Skindex-29, a 
validated 29-item instrument to measure the effects of skin 
diseases on quality of life [6,17]. Results are reported in 
3 areas affecting quality of life: emotions, symptoms, and 
effect size (d) (difference in the mean values between the fi rst 
and follow-up visits divided by the mean SD of the 2 time 
points) [18] and statistical signifi cance was calculated using 
the Wilcoxon signed rank test. The Pearson χ2 was used to 
determine the correlation between cognitive fl exibility and 
course of urticaria. 
Results
Patients
Of the 112 patients suffering from chronic urticaria, 
95 were included in the study and completed the PRISM 
task. Seventeen patients could not be enrolled: 8 refused to 
participate, 8 could not understand the questionnaire due to 
linguistic diffi culties, and 1 was younger than 12 years of age. 
The mean age of the 95 enrolled patients was 39.3 (13.6) years 
(range, 16 to 79 years) and 55 (58%) were women. Median 
(interquartile range) duration of chronic urticaria at the fi rst 
visit was 25.6 (13.9-116.3; range, 3-821) months. During the 
fi rst visit, 64 patients completed the DLQI and Skindex-29 
questionnaires. At the follow-up visit, 88 patients completed 
the PRISM and 57 completed the DLQI and Skindex-29. 
Seven patients did not complete the follow-up PRISM and 7 
patients did not complete the follow-up DLQI or Skindex-29 
(Figure 2).
High Burden of Suffering in Chronic Urticaria 
Patients
The SIS was high in the 64 patients who completed PRISM, 
DLQI, and Skindex-29 at their fi rst visit (110.7 [75.2] mm; 
maximum score, 40.6 [27.5%]). Mean DLQI in the same 
112 patients urticaria consultation
95 patients PRISM = 1x
64 patients HRQOL = 1x
17 patients no PRISM
48 patients no HRQOL
88 patients PRISM = 2x
57 patients HRQOL  = 2x
7 patients lost to
PRISM follow-up
7 patients lost to
HRQOL  follow-up
Figure 2. Flowchart of patients. Of the 112 urticaria patients attended at the specialty 
clinic, 95 were enrolled for PRISM. At the fi rst visit, 64 patients had completed both HRQOL 
questionnaires. PRISM was completed at follow-up by 88 patients; PRISM and HRQOL were 
completed at the follow-up visit by 57 patients. 1x; on fi rst visit, 2x: on fi rst and on follow-up 
visit. HRQOL indicates health-related quality of life; PRISM, Pictorial Representation of Illness 
and Self Measure.
functioning. A composite score (average scale 
score) was calculated to measure overall impact 
on quality of life. Higher Skindex-29 scores 
indicate greater effects on quality of life.
All patients were assessed by the same 
investigator and completed the PRISM task, 
DLQI, and Skindex-29 in the urticaria specialty 
clinic at their fi rst visit and at the follow-up 
visit. 
Two case reports are presented to demonstrate 
the diagnostic and therapeutic importance of 
PRISM.
Statistical Analysis
Data were analyzed using SPSS 11.5 
(SPSS Inc., Chicago, Illinois, USA). PRISM, 
DLQI, and Skindex-29 scores at the first 
visit and follow-up visit were expressed 
as absolute mean (SD) and as percentage 
mean (SD) of maximum scores. Correlations 
between PRISM, DLQI, and Skindex-29 were 
expressed using the Spearman rank correlation 
coeffi cient (ρ). Changes in PRISM, DLQI, 
and Skindex-29 scores between the fi rst and 
follow-up visits were expressed as the Cohen 
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patients was 10.2 (6.2) (maximum score, 34.0 [20.7%]); mean 
Skindex-29 was 38.1 (21.6) (maximum score, 32.8% [18.6%]) 
(data not shown).
PRISM correlated moderately with DLQI and Skindex-29 
(Spearman rank correlation coeffi cient ρ=–0.46 [P<.001] and 
ρ=–0.43 [P<.001], respectively). 
DLQI and Skindex-29 Indicate an Improvement in 
Health-Related Quality of Life Over Time, but No 
Improvement in PRISM
In the 57 patients who completed PRISM, DLQI, and 
Skindex-29 at both time points, DLQI and Skindex-29 
showed an improvement in quality of life over time. DLQI 
Table. Change in Suffering Between the First and Follow-up Visita 
   
   n=57  Mean 0 Mean 1 SD0 SD1 Effect Size, d P Value
PRISM, mm 41.11 48.72 32.07 35.65 0.22443557 .085
Skindex-29 32.74 23.58 20.38 20.23 0.45111734 <.001
DLQI 32.03 18.93 21.27 20.9 0.62127085 <.001
Skindex-29 symptoms 37.36 27.48 18.64 20 0.5110707 <.001
Skindex-29 emotions 36.52 28.09 21.67 23.52 0.37277914 <.001
Skindex-29 social 
functioning 23.46 17.55 21.45 20.58 0.28116747 < 0.001
Abbreviations: DLQI, Dermatology Life Quality Index; PRISM, Pictorial Representation of Illness and Self Measure.
aDifference in the mean values between fi rst (M0) and follow-up visit (M1) divided by the mean SD of the 2 time points. Expressed by the Cohen
 effect size (d) and level of signifi cance (P) (Wilcoxon signed rank test) 
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Figure 3. Cognitive fl exibility correlates with better outcome in chronic urticaria.
Infl exible, Patients assessed as cognitively infl exible by PRISM at the fi rst visit. Flexible, better, Patients with 
improvement in burden of suffering between the fi rst visit and 2 weeks before. Flexible, worse, patients 
with deterioration of suffering at the fi rst visit compared to 2 weeks before (P=.007, Pearson χ2). Outcome 
relates to days with urticaria symptoms reported by patients at the follow-up visit. Improvement, Reduction 
in the number of days with urticaria symptoms by at least 25% within the last month before the follow-up 
visit. Unchanged, Improvement less than 25% or deterioration of urticaria. PRISM indicates Pictorial 
Representation of Illness and Self Measure.
was 9.6 (6.4) (maximum score, 32.0 [21.3%]) at the fi rst visit 
and 5.7 (6.3) (maximum score, 18.9 [20.9%]) at the follow-up 
visit (Cohen effect size, d=0.62; P<.001). Skindex-29 was 
37.9 (23.7) (maximum score, 32.7% [20.4%]) at the fi rst visit 
and 27.4 (23.4) (23.6 [20.2%] maximum score) at the follow-
up visit (Cohen effect size, d=0.45; P<.001). In contrast to the 
2 health-related quality of life questionnaires, PRISM remained 
unchanged over time: SIS was 112.2 (87.6) mm (maximum score, 
41.1 [32.1%]) at the fi rst visit and 133.0 (97.5) mm (maximum 
score, 48.7 [35.7%]) at the last visit (Cohen effect size, d=0.22; 
P=.085) (Table and Figure 3). Skindex-29 subscores for the 3 
areas symptoms, emotions, and social functioning were similar 
to the composite Skindex-29 scores (Table).
PRISM: Suffering in Chronic Urticaria
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Figure 4. From the baseline visit to the follow-up visit, the Skindex-29 and DLQI scores indicate an improvement in quality of life, whereas the PRISM score 
remains unchanged. Left, absolute mean scores for PRISM (mm), DLQI, and Skindex-29.  Right, Percent mean values of respective maximum scores. 
aP<.001 (Wilcoxon signed rank test). N=57 patients. In PRISM, high scores represent little suffering, whereas in Skindex-29 and DLQI high scores 
represent considerable impairment in quality of life. DLQI indicates Dermatology Life Quality Index; NS, nonsignifi cant; PRISM, Pictorial Representation 
of Illness and Self Measure.
Cognitive Flexibility Correlates With Better 
Outcome of Chronic Urticaria
In a subset of 66 patients who were assessed for cognitive 
fl exibility at the fi rst visit using PRISM and who had a complete 
clinical follow-up, 12 were infl exible, 21 fl exible, worse, and 
33 fl exible, better. Disease course was favorable signifi cantly 
more often in cognitively fl exible patients than in cognitively 
infl exible patients (P=.007, Pearson chi-square test) (Figure 
4). This was not only true for patients reporting improvement 
in burden of suffering between the fi rst visit and the previous 
2 weeks (fl exible, better), but also for those reporting increased 
burden of suffering (fl exible, worse). 
Case Descriptions
Patient 1 (Fears): A 45-year-old man had a 2-year 
history of chronic idiopathic urticaria with angioedema. The 
wheals appeared daily. All diagnostic tests were negative 
and no specifi c etiology could be identifi ed. In the PRISM 
task–administered at the fi rst visit–the patient placed the 
urticaria disk directly on top of the self disk (SIS, 0 mm). DLQI 
and Skindex-29 showed high scores (17 and 85, respectively). 
Symptomatic therapy with antihistamines was started. At his 
next visit 2 months later the patient reported that all wheals 
had completely disappeared. DLQI and Skindex-29 scores 
showed a clear reduction (5 and 43, respectively). Surprisingly, 
once again, he placed the illness disk directly on top of the 
self disk (SIS, 0 mm). When asked why he still felt such a 
considerable burden of suffering, he answered that he was 
afraid of developing angioedema again and suffocating.
This case illustrates that PRISM may help clinicians to 
better understand a patient’s perception of disease, as well as 
the implications and assumed complications of the disease. 
The clinician was able to reassure the patient by explaining 
to him the mechanisms of the disease and by pointing out 
that, unlike other forms of angioedema (eg, C1 inhibitor 
defi ciency), angioedema associated with chronic urticaria 
is extremely unlikely to cause asphyxiation. He provided 
the patient with a set of tablets for emergency situations. At 
the last visit, we not only observed a stable reduction in his 
DLQI and Skindex-29, but also a clear improvement in the 
PRISM score SIS (145 mm). This case demonstrates how 
PRISM can reveal and make it possible to address factors 
that negatively affect a patient’s burden of suffering and that 
could be missed by administering the health-related quality 
of life questionnaires alone. 
Patient 2 (Close medical attendance): A 58-year-old woman 
with a 2-year history of urticaria vasculitis with angioedema 
presented with daily wheals and unbearable pruritus. Therapy 
with antihistamines and prednisone were ineffective. In the 
PRISM task, she placed the illness disk in the middle of the 
white board (SIS, 130 mm). When asked why the urticaria 
disk was at such a distance from her despite her severe daily 
symptoms, she answered that the mere fact of being admitted 
to an urticaria specialty clinic had diminished her suffering. 
Therapy was started with dapsone and, at her follow-up visit 
4 months later, she reported feeling much better, as almost no 
wheals and only minimal pruritus had occurred. During the 
PRISM task, she placed the disk outside the board (SIS, 273 
mm). In this case, the patient was able to express her feelings 
nonverbally by PRISM, which helped the clinician to understand 
that close and intensive medical attendance alone could reduce 
the burden of suffering. Regular visits to an urticaria specialty 
clinic may better meet these patients’ needs.
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In this case, the DLQI and Skindex-29 showed relatively 
good scores at the fi rst visit and an improvement over time; 
however, as these instruments do not provide an opportunity 
for the patient to freely express his/her feelings, they were not 
able to identify her need for close medical attendance. 
Discussion
The aim of this study was to assess the burden of suffering 
and impairment of quality of life in patients with chronic 
urticaria and to compare PRISM with 2 self-administered 
quality of life questionnaires, DLQI and Skindex-29. 
PRISM has been validated in a variety of dermatological and 
nondermatological diseases to measure burden of suffering 
[7,8]. Given that the clinician’s view of impairment and the 
patient’s perception do not necessarily correlate [14], burden 
of suffering is an important indicator in the management 
of the disease [19]. In our study, 95 patients with chronic 
urticaria were monitored over a period of 4 months. Patient 
characteristics were similar to those reported in other studies 
on chronic urticaria, with 55 (58%) women and a mean age of 
39.3 (13.6) years [20]. We found that most patients (94.7%) 
had spontaneously occurring urticaria and that only 5 patients 
(5.3%) were suffering from physical urticaria. Since there 
may be differences in the burden of suffering between the 
various types of physical urticaria and spontaneously occurring 
urticaria (autoimmune, idiopathic), larger-scale studies should 
be performed to assess these forms separately. 
High Burden of Suffering and Quality of Life 
Impairment in Chronic Urticaria
Several studies have found that patients with chronic 
urticaria experience impaired quality of life [19,21-25]. 
Although rarely life-threatening, chronic urticaria in adult 
patients has been shown to have an impact on quality of 
life comparable to that of patients with severe coronary 
artery disease awaiting bypass surgery [22]. Poon et al [23] 
found that the impaired quality of life in chronic urticaria 
patients was similar to that of acne patients and higher 
than in patients suffering from vitiligo, both of which 
skin diseases are known to signifi cantly affect quality of 
life. Consistent with these observations, we found highly 
impaired quality of life in our urticaria patients using DLQI 
and Skindex-29. PRISM revealed a very high burden of 
suffering in our patients, as it has already done in patients 
with other chronic diseases, such as rheumatoid arthritis, 
chronic obstructive pulmonary disease, and systemic lupus 
erythematosus [14]. 
Moderate Correlation Between PRISM, DLQI, and 
Skindex-29
The correlation between PRISM, DLQI, and Skindex-29 
was moderate (r=–0.43, –0.47, respectively), whereas DLQI 
and Skindex-29 correlate much better (r=0.77) (data not 
shown). We had expected correlations between PRISM and 
the quality of life questionnaires to be moderate or poor, as 
PRISM is not primarily intended to measure quality of life, 
but burden of suffering, which partly overlaps with quality of 
life, even though it is not exactly the same. 
Quality of Life Measures Improve Under Treatment, 
Burden of Suffering Does Not
In our cohort, DLQI and Skindex-29 showed a signifi cant 
improvement in quality of life between the fi rst visit and 
the follow-up visit. However, the PRISM score remained 
unchanged. This was a surprising fi nding and there may be 
several explanations for it. First, PRISM assesses burden of 
suffering, whereas DLQI and Skindex-29 measure quality 
of life. Burden of suffering refl ects a person’s perception of 
the intrusiveness and controllability of his/her illness [26] 
and includes those fears that exacerbate burden of suffering. 
DLQI and Skindex-29, however, are designed to measure 
and compare disability in different skin diseases and measure 
other psychological aspects. DLQI and Skindex-29 measure 
disability in the preceding week only and thus provide a true 
picture only in those patients who had active disease. Neither 
of the 2 questionnaires is disease-specifi c and may assess 
some dimensions of quality of life that have little relevance 
for patients with chronic urticaria, eg, how time-consuming 
therapy is or the fear of getting scars. Second, PRISM considers 
the chronicity of urticaria, which often has a relapsing and 
unpredictable course. PRISM provides a comprehensive 
measure of burden of suffering and may yield additional and, 
possibly, more suitable information on a patient’s psychological 
situation than quality of life questionnaires alone. 
Cognitive Flexibility Correlates With Better 
Outcome in Chronic Urticaria
Our study showed a positive correlation between cognitive 
fl exibility, as assessed by PRISM at the baseline visit, and 
better outcome in chronic urticaria. Interestingly, both patients 
reporting improvement in urticaria for the 2 weeks preceding 
the baseline visit (fl exible, better) and those patients reporting 
deterioration of urticaria at the baseline visit (fl exible, worse) 
had a signifi cantly better outcome than cognitively infl exible 
patients. The literature does not provide suffi cient evidence 
that cognitive fl exibility or a specifi c state of mind could 
directly affect the clinical outcome of urticaria. However, it 
is conceivable that cognitive fl exibility affects behavior and 
adherence to treatment, including taking medication resulting 
in a distinct clinical outcome. We conclude that cognitive 
fl exibility as assessed by PRISM could be a predictor of a 
positive outcome in chronic urticaria. If this fi nding can be 
reproduced in larger studies, we recommend that PRISM be 
used to identify patients prone to developing refractory disease 
and to assign them to a more intensive and comprehensive 
treatment regimen. 
PRISM has several advantages. It requires only simple 
instructions and little time to complete (2-3 minutes in our 
patients). We found that patients liked to perform this task and 
that it facilitated the approach to uncommunicative patients. 
Rumpf et al [27] recently reported a self-administered version 
of PRISM. However, it is exactly the direct interaction between 
patient and clinician that makes PRISM a unique instrument 
for improved understanding and therapy planning. Our 2 
PRISM: Suffering in Chronic Urticaria
 J Investig Allergol Clin Immunol 2011; Vol. 21(2): 93-100© 2011 Esmon Publicidad
case reports illustrate that PRISM facilitates patient–clinician 
communication and may have a positive effect on therapy 
and outcome. The importance of the quality of interaction 
and communication with patients was recently proven in an 
online study by Maurer et al [28], who reported that patients 
suffering from chronic urticaria whose clinicians had also 
discussed emotional aspects of their disease with them were 
signifi cantly more satisfi ed with treatment and more trusting 
in their physician. 
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